Independent
Tenure on this board
2.7 yrs
Also a director at
Immatics NV (IMTX)
8 nominees · 4 ballot items.
Election of eight directors; advisory (non-binding) vote to approve executive compensation (Say-on-Pay); approval of the Amended and Restated 2006 Stock Incentive Plan to increase authorized shares from 17,475,171 to 20,975,171 and amend terms; ratification of Kesselman & Kesselman as independent auditors for 2026.
Elect eight directors to serve for one-year terms until successors are elected and qualified.
Non-binding advisory vote to approve compensation of the named executive officers as disclosed in the proxy statement.
The proposal asks shareholders to cast a non-binding advisory vote to approve the company’s executive compensation disclosures and overall compensation decisions for Named Executive Officers as detailed in the proxy statement. Management seeks this vote to obtain shareholder feedback and demonstrate support for its pay practices; the outcome will not be binding but will be considered by the Board and Compensation Committee when setting future pay. The company frames its compensation program as pay-for-performance, aligning incentives to long-term shareholder value, with a mix of base salary, discretionary bonuses tied to corporate and strategic milestones, and equity grants under its stock incentive plan; it highlights recent grants, retention awards, and change-in-control protections. The Board recommends FOR, arguing that the program is competitive, aligns pay with performance, and supports retention. Key context includes recent equity awards, accelerated vesting on change-in-control, and the company’s transition of strategic focus to PRX-115 and commercialization support for pegunigalsidase alfa. Potential investor concerns include discretionary bonus decisions, change-in-control payouts, and the scale of equity grants relative to shareholder dilution; however, the company emphasizes transparency and historical performance considerations in its recommendations.
Approve amendment and restatement of 2006 Stock Incentive Plan to increase shares reserved under the Plan by 3,500,000 to 20,975,171 and amend certain other terms including extending the termination date.
This management proposal requests shareholder approval to amend and restate the company’s long-standing 2006 Stock Incentive Plan to add 3.5 million shares, increasing the reserve to 20,975,171 shares, remove the Section 162(m) provision, and extend the plan termination date (now to April 23, 2036). Management argues this increase is necessary to continue attracting, retaining, and motivating employees, directors, and consultants through equity-based compensation, maintain competitive pay practices, and support long-term alignment with stockholders. The amendment’s context includes existing outstanding awards (8,274,278 options) and only ~2.09 million shares available under the current cap — leaving limited headroom for future grants. The Board unanimously approved the amendment, recommending a FOR vote due to anticipated talent needs and the importance of equity incentives for pipeline development and commercialization efforts. Analysts should consider potential dilution (additional ~3.5M shares), the accounting and equity-overhang implications, and the governance changes (removal of 162(m) provisions, extended term) which may affect tax deductibility and compensation governance norms. The plan’s detailed provisions on vesting, change-in-control acceleration, and Israeli tax-compliant mechanisms are included in Appendix A; the amendment preserves board discretion on grant timing and award types. Risks include shareholder dilution, re-pricing or exchange mechanics, and whether equity remains the most efficient retention tool; benefits are continued ability to grant meaningful equity to support R&D and commercial objectives. The Board’s recommendation is FOR with rationale centered on talent retention and operational flexibility.
Ratify selection of Kesselman & Kesselman (a member of PwC network) as independent auditors for fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MAK CAPITAL ONE LLC | 4.40% | 3,544,139 | $8M |
| 2 | BlackRock, Inc. | 3.06% | 2,462,918 | $5M |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1.52% | 1,224,800 | $3M |
| 4 | STATE STREET CORP | 1.21% | 972,815 | $2M |
| 5 | BlackRock, Inc. | 0.97% | 780,785 | $2M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 0.96% | 771,950 | $2M |
| 7 | NORTHERN TRUST CORP | 0.63% | 504,678 | $1M |
| 8 | Stratos Wealth Partners, LTD. | 0.62% | 500,000 | $1M |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 0.54% | 432,485 | $938K |
| 10 | Prospera Financial Services Inc | 0.52% | 418,570 | $908K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.